A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.
about
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review.A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
P2860
A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
A phase III trial of exemestan ...... cizumab: a GINECO group study.
@en
A phase III trial of exemestan ...... cizumab: a GINECO group study.
@nl
type
label
A phase III trial of exemestan ...... cizumab: a GINECO group study.
@en
A phase III trial of exemestan ...... cizumab: a GINECO group study.
@nl
prefLabel
A phase III trial of exemestan ...... cizumab: a GINECO group study.
@en
A phase III trial of exemestan ...... cizumab: a GINECO group study.
@nl
P2093
P2860
P356
P1433
P1476
A phase III trial of exemestan ...... cizumab: a GINECO group study.
@en
P2093
C Jouannaud
D Béal-Ardisson
E Guardiola
E Pujade-Lauraine
H Orfeuvre
P2860
P304
P356
10.1093/ANNONC/MDW077
P577
2016-02-24T00:00:00Z